Kenvue, Inc. (KVUE) Stock Price & Analysis
KVUE Stock Chart & Stats
- Day’s Range
- MXN 375.00 - MXN 376.00
- 52-Week Range
- MXN 262.73 - MXN 376.00
- Previous Close
- MXN 365.00
- Volume
- 0
- Average Volume (3M)
- 72
- Market Cap
- MXN 697.00B
- Enterprise Value
- MXN 41.58B
- Total Cash (Recent Filing)
- MXN 1.04B
- Total Debt (Recent Filing)
- MXN 8.34B
- Price to Earnings (P/E)
- 21.9
- Beta
- -0.05
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- 4.89
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 4.71%
Bulls Say, Bears Say
Bulls Say
Sustained Sales Growth And Execution
Four consecutive quarters of net and organic sales growth indicate improving execution and product demand across the portfolio. Combined with margin expansion and strong cash generation, this supports a more durable recovery in operating performance over the next several quarters.
Strong Profitability And Cash Generation
Kenvue’s strong margins and substantial free cash flow provide resources to reinvest in brands, innovation, and productivity while supporting financial obligations. High free cash flow relative to net income also indicates that reported earnings are translating into meaningful cash generation.
Diversified Consumer-health Portfolio
Kenvue’s broad portfolio spans recurring everyday-health categories, including self-care, skin health, oral care, and hygiene. Distribution through retailers, pharmacies, grocery, e-commerce, and other outlets gives the company multiple routes to consumers and supports brand reach.
Bears Say
Meaningful Leverage Limits Flexibility
Although the capital structure is described as manageable, debt remains meaningful relative to equity and can constrain financial flexibility if operating conditions weaken. Leverage may also limit the capacity to fund growth initiatives or absorb weaker cash generation without adjusting capital allocation.
History Of Earnings And Cash-flow Volatility
The recovery in profitability is encouraging, but the prior decline and uneven cash-flow conversion show that earnings quality has not been perfectly consistent across periods. This variability makes future operating results and internally generated funding less predictable than current TTM figures suggest.
Acquisition-related Debt And Reporting Changes
The planned acquisition introduces execution and financing complexity as Kenvue debt is integrated into Kimberly-Clark’s structure. Amendments removing covenants and reporting obligations may increase flexibility, but they also change creditor protections and the risk profile during integration.
Kenvue, Inc. News
Filippo Falorni Reiterates Hold on Kenvue, Keeps Price Target Unchanged at $19 Amid Renewed Tylenol Litigation Risks
Kenvue, Inc., the Consumer Defensive sector company, was revisited by a Wall Street analyst yesterday. Analyst Filippo Falorni from Citi maintained a Hold rating on the stock and has a
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
What is Kenvue, Inc.’s market cap?
When is Kenvue, Inc.’s upcoming earnings report date?
How were Kenvue, Inc.’s earnings last quarter?
Is Kenvue, Inc. overvalued?
Does Kenvue, Inc. pay dividends?
What is Kenvue, Inc.’s EPS estimate?
How many shares outstanding does Kenvue, Inc. have?
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Kenvue, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Kenvue, Inc. Stock Smart Score
Company Description
Kenvue, Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
- Sector
- Consumerdefensive
- Industry
- Household & Personal Products
- CEO
- Kirk L. Perry
- Employees
- 21,890
- Website
- www.kenvue.com
- Address
- 1 Kenvue Way, Summit, NJ, 07901, US
Kenvue, Inc. (KVUE) Earnings & Revenues
KVUE Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted Kenvue's strengths in market share gains and leadership improvements but was overshadowed by underwhelming financial performance and challenges in key markets. The revised guidance and focus on strategic alternatives suggest a period of transition and uncertainty.
View all MX:KVUE earnings summariesKVUE Net sales Breakdown
- 42.17% Self Care
- 27.20% Skin Health and Beauty
- 30.63% Essential Health
KVUE Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 0 | 6 |
| Technical Analysis | 3 | 0 | 6 |
| Moving Averages | 12 | 0 | 0 |









